

FOR IMMEDIATE RELEASE

June 11, 2010

Pfizer Japan Inc.
Eisai Co., Ltd.

**Pfizer, Eisai to launch postherpetic neuralgia drug
Lyrica[®] Capsules on June 22**

Tokyo, Japan, June 11, 2010 Pfizer Japan Inc. (Head Office: Tokyo; President: Ichiro Umeda) and Eisai Co., Ltd. (Headquarters: Tokyo; President & CEO: Haruo Naito) announced that the two companies will launch postherpetic neuralgia treatment Lyrica[®] Capsules (generic name: pregabalin) on June 22, 2010.

Lyrica[®] was approved in Japan on April 16 of this year and was today listed in the NHI drug price list. Pfizer Japan and Eisai are jointly promoting sale of the drug and work together to ensure the provision of information regarding its proper usage.

Developed by Pfizer Inc. (USA), Lyrica[®] is currently approved in over 105 countries worldwide. Its major mechanism of action is thought to express its analgesic effects by suppressing the output of

